According to a new study, seek-and-destroy gene therapeutic system may potentially treat prostate cancer in the near future.
Researchers from the University of Strathclyde and the Beatson Institute in the UK have revealed that seek-and-destroy gene therapy stopped the growth of majority of prostate tumors in the laboratory models.
The researchers used the new system therapy against two types of prostate tumor, with 70 per cent of tumor in one type and 50 per cent on the other, which were completely removed over a period of one month. The findings were published in the journal Drug Delivery in February 2019, issue.
Christine Dufes, a senior lecturer at the University of Strathclyde and lead researcher of the study, said: “Although some treatments, including chemotherapy and radiotherapy, can be effective against localized tumors, there is still no effective treatment for patients whose cancer recurs or spreads.”
The team believes that the new therapy seems highly promising for the treatment of prostate cancer, however they have yet to find a suitable delivery system, which can selectively deliver the therapeutic genes to the tumors without adverse side effects for healthy tissues.
"To address this, we develop a new 'seek-and-destroy' nanomedicine linked to an iron-carrying protein called lactoferrin, whose receptors are found in large amounts in many cancers. The results show that it is highly promising for the treatment of prostate cancer by gene therapy," Dufes explained.
The research was funded by Science Communications Manager at Worldwide Cancer Research.
Subscribe to our newsletter to get notification about new updates,information, discount, etc..